ESC 365 - ASCVD & residual risk: recent clinical insights with icosapent ethyl.

Open Access

ASCVD & residual risk: recent clinical insights with icosapent ethyl.

Session: New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice

Topic: Lipid-Lowering Agents

Speaker: Professor D. Bhatt (New York, US)

Organised by PACE-CME - Supported by an unrestricted educational grant from Amarin Pharma

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York (United States of America)

44 presentations

7 followers

4 more presentations in this session

Introduction.

Speaker: Professor L. Badimon (Barcelona, ES)

A continuum of multifactorial benefits of icosapent ethyl.

Speaker: Professor M. Back (Stockholm, SE)

Integrating icosapent ethyl in clinical practice: which patients will benefit?

Speaker: Professor S. Verma (Toronto, CA)

Discussion.

Speaker: Professor L. Badimon (Barcelona, ES)

Access the full session

New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice

Speakers: Professor D. Bhatt, Professor L. Badimon, Professor M. Back, Professor S. Verma, Professor L. Badimon

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources